While feasible to manufacture in a heavily pretreated population, L1CAM may not be an appropriate target in neuroblastoma. Additional engineering strategies may be needed to prevent toxicity and provide durable anti-tumor effects.

21 hours ago

P1 data • Journal • First-in-human

L1CAM (L1 cell adhesion molecule)

21h

Therapy of melanoma : Current standards and future perspectives (PubMed, Pathologie (Heidelb))

Multimodal treatment strategies have fundamentally improved the prognosis of melanoma. Therapy selection should be individualized based on molecular markers and disease stage. Future developments aim to integrate combination strategies, personalized immunotherapeutic approaches, and the overcoming of resistance mechanisms.

21 hours ago

Review • Journal • IO biomarker

LAG3 (Lymphocyte Activating 3)

BRAF mutation • BRAF V600

Nidlegy (darleukin/fibromun)

Mel73: Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma (clinicaltrials.gov)

P=N/A, N=66, Not yet recruiting, University of Virginia

2 days ago

New trial

Integrated transcriptomics identifies HIF1A and GSTP1 as biomarkers for cutaneous squamous cell carcinoma. (PubMed, Transl Cancer Res)

Drug prediction and docking identified camptothecin, hydroquinone, and resveratrol with favorable binding (e.g., HIF1A-camptothecin -8.7 kcal/mol; GSTP1-camptothecin -8.6 kcal/mol)...Keratinocyte pseudotime revealed progression from normal to metastatic states with concordant keratinocyte‑related gene programs. HIF1A and GSTP1 are promising diagnostic biomarkers for cSCC, linked to altered immune landscapes, enhanced intercellular signaling, and potential druggable interactions.

2 days ago

Journal

CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • GSTP1 (Glutathione S-transferase pi 1)

Cutaneous clear cell sarcoma (PubMed, Pathologie (Heidelb))

Molecular confirmation of the EWSR1 rearrangement is desirable for diagnosis, as the differentiation from other neoplasms, including melanoma and CRTC1::TRIM11 cutaneous tumours, has important therapeutic and prognostic consequences.

2 days ago

Review • Journal

EWSR1 (EWS RNA Binding Protein 1) • PRAME (Preferentially Expressed Antigen In Melanoma) • ATF1 (Activating Transcription Factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1) • CREM (CAMP Responsive Element Modulator) • CRTC1 (CREB Regulated Transcription Coactivator 1)

GustaborRCT: Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention (clinicaltrials.gov)

P=N/A, N=198, Not yet recruiting, Wuerzburg University Hospital

3 days ago

New trial

ircAE: Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy (clinicaltrials.gov)

P=N/A, N=255, Completed, National Jewish Health | Recruiting --> Completed

3 days ago

Trial completion • Trial completion date • Adverse events • IO biomarker

ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

3 days ago

Trial completion • Trial completion date

doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors (clinicaltrials.gov)

P=N/A, N=80, Recruiting, Alpha Tau Medical LTD. | Trial completion date: Jan 2025 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Jan 2027

3 days ago

Trial completion date • Trial primary completion date